Product Description
For healthy patients with cutaneous warts
Mechanisms of Action: Sodium Potassium ATPase Inhibitor,NKCC Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Maruho
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Warts
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CLS003-CO-PR-003 | P2 |
Terminated |
Warts |
2018-10-30 |
60% |
2019-06-14 |
Treatments |
| CLS003-CO-PR-002 | P2 |
Completed |
Warts |
2015-08-01 |
2019-06-14 |
||
| CLS003-CO-PR-001 | P2 |
Completed |
Warts |
2014-04-01 |
2019-06-14 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|